The BluePearl Pet Hospital in Tampa, Florida, is now offering the transcatheter edge-to-edge repair (TEER) procedure for its ...

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

Objective: To evaluate contractile reserve (CR) determined by exercise echocardiography in predicting clinical outcome and left ventricular (LV) function in asymptomatic severe mitral regurgitation ...

Edwards SAPIEN M3 mitral valve replacement system receives CE Mark for transcatheter treatment: Irvine, California Wednesday, ...

Mitral regurgitation is the most common form of valvular heart disease and affects around 10% of Americans over 75. It occurs when the mitral ...

The first-of-its-kind Edwards Lifesciences Sapien M3 TMVR system uses a nitinol dock to anchor the replacement valve in the patient's heart.

Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

After acquiring its developer last year, Edwards Lifesciences has now obtained a European approval for what it described as ...

Navi Mumbai: A 78-year-old patient with severe mitral regurgitation has successfully undergone the MitraClip procedure, marking a significant advancement in minimally invasive heart care.